Anthony J. Calandra

Array ( [id] => 20466557 [patent_doc_number] => 12522589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Synthesis of CRAC channel inhibitors [patent_app_type] => utility [patent_app_number] => 18/252695 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10330 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246782 [patent_doc_number] => 11603355 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Charged ion channel blockers and methods for use [patent_app_type] => utility [patent_app_number] => 17/095949 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41547 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 436 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18257055 [patent_doc_number] => 20230084095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/773607 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 1222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17081960 [patent_doc_number] => 20210276966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors [patent_app_type] => utility [patent_app_number] => 17/078055 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17078055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761012 [patent_doc_number] => 20210106593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => SERINE/THREONINE KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/075380 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925190 [patent_doc_number] => 11046651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Piperazine substituted azapine derivatives and uses thereof [patent_app_type] => utility [patent_app_number] => 17/075468 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 66285 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938341 [patent_doc_number] => 11472782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => RIP1 inhibitory compounds and methods for making and using the same [patent_app_type] => utility [patent_app_number] => 17/072862 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28764 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 217 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16597944 [patent_doc_number] => 20210024475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => CRYSTAL MODIFICATIONS OF ODEVIXIBAT [patent_app_type] => utility [patent_app_number] => 17/065245 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18763995 [patent_doc_number] => 11814381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Pyrazolopyridine derivative having GLP-1 receptor agonist effect [patent_app_type] => utility [patent_app_number] => 17/065122 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 35406 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543096 [patent_doc_number] => 20240360132 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-10-31 [patent_title] => TRICYCLIC KINASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/766520 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -113 [patent_words_short_claim] => 673 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18853883 [patent_doc_number] => 11851444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Redox active materials, processes and uses thereof [patent_app_type] => utility [patent_app_number] => 17/766496 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 27 [patent_no_of_words] => 13575 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543096 [patent_doc_number] => 20240360132 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-10-31 [patent_title] => TRICYCLIC KINASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/766520 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -113 [patent_words_short_claim] => 673 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711836 [patent_doc_number] => 20210078983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/948770 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753926 [patent_doc_number] => 20230357271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => MACROCYCLIC COMPOUND [patent_app_type] => utility [patent_app_number] => 18/028578 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16568972 [patent_doc_number] => 20210007978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => Fixed Dose Oral Testosterone Undecanoate Compositions and Use Thereof [patent_app_type] => utility [patent_app_number] => 17/033198 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413081 [patent_doc_number] => 11667613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Antiviral pyrazolopyridinone compounds [patent_app_type] => utility [patent_app_number] => 17/030540 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86646 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467617 [patent_doc_number] => 11274085 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors [patent_app_type] => utility [patent_app_number] => 17/031815 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16512 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 802 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17490392 [patent_doc_number] => 11279681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors [patent_app_type] => utility [patent_app_number] => 17/031814 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48999 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 846 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467616 [patent_doc_number] => 11274084 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors [patent_app_type] => utility [patent_app_number] => 17/031812 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18805 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 778 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858488 [patent_doc_number] => 11439626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Controlled release formulations of riluzole and their uses [patent_app_type] => utility [patent_app_number] => 17/026181 [patent_app_country] => US [patent_app_date] => 2020-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 34 [patent_no_of_words] => 18343 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026181 [rel_patent_id] =>[rel_patent_doc_number] =>)